CBIO (Crescent Biopharma) ROCE % : 0.00% (As of Dec. 2024)

View and export this data going back to 2025. Start your Free Trial

What is Crescent Biopharma ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Crescent Biopharma's annualized ROCE % for the quarter that ended in Dec. 2024 was 0.00%.

Crescent Biopharma ROCE % Historical Data

The historical data trend for Crescent Biopharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Crescent Biopharma ROCE % Chart

Crescent Biopharma Annual Data

Trend

Dec24

ROCE %

Crescent Biopharma Semi-Annual Data
	Dec24
ROCE %	-

Crescent Biopharma ROCE % Calculation

Crescent Biopharma's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: . 20 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: . 20 )		(A: Dec. 2024 )
	=		/	( ( ( - )	+	( - ) )	/ )
	=		/	( (	+	)	/ )
	=		/
	=	%

Crescent Biopharma's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: . 20 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: . 20 )		(Q: Dec. 2024 )
	=		/	( ( ( - )	+	( - ) )	/ )
	=		/	( (	+	)	/ )
	=		/
	=	%

(1) Note: The EBIT data used here is one times the annual (Dec. 2024) EBIT data.

Crescent Biopharma (NAS:CBIO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Crescent Biopharma ROCE % Related Terms

Thank you for viewing the detailed overview of Crescent Biopharma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Crescent Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Crescent Biopharma Inc (NAS:CBIO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

221 Crescent Street, Suite 105, Building 23, Waltham, MA, USA, 02453

Website

https://www.crescentbiopharma.com

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.